APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antibody Drug Conjugates (ADCs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antibody Drug Conjugates (ADCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173965810320 December 2025196 pages

Choose your research edition.

Industry ResearchAntibody Drug Conjugates (ADCs) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody Drug Conjugates (ADCs) Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antibody Drug Conjugates (ADCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody Drug Conjugates (ADCs) Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody Drug Conjugates (ADCs) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Antibody Drug Conjugates (ADCs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antibody Drug Conjugates (ADCs) include AbGenomics, ADC Therapeutics, Astellas Pharma, Genmab, Kairos Therapeutics, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Antibody Drug Conjugates (ADCs) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody Drug Conjugates (ADCs) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody Drug Conjugates (ADCs) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Antibody Drug Conjugates (ADCs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibody Drug Conjugates (ADCs) Segment by Company

AbGenomics

ADC Therapeutics

Astellas Pharma

Genmab

Kairos Therapeutics

Seattle Genetics

Takeda Pharmaceuticals

AbbVie

Bayer

Pfizer

Roche

Novartis

Antibody Drug Conjugates (ADCs) Segment by Type

Seattle Genetics Technology

Immunomedics Technology

ImmunoGen Technology

Antibody Drug Conjugates (ADCs) Segment by Application

Hospital

Clinics

Others

Antibody Drug Conjugates (ADCs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug Conjugates (ADCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug Conjugates (ADCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug Conjugates (ADCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Antibody Drug Conjugates (ADCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody Drug Conjugates (ADCs) industry.

Chapter 3: Detailed analysis of Antibody Drug Conjugates (ADCs) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug Conjugates (ADCs)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Seattle Genetics Technology Table 3. Key Players of Immunomedics Technology Table 4. Key Players of ImmunoGen Technology Table 4. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Clinics Table 7. Key Players of Others Table 8. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Antibody Drug Conjugates (ADCs) Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Antibody Drug Conjugates (ADCs) Market Share by Region (2021-2026) Table 11. Global Antibody Drug Conjugates (ADCs) Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Antibody Drug Conjugates (ADCs) Market Share by Region (2027-2032) Table 13. Antibody Drug Conjugates (ADCs) Industry Trends Table 14. Antibody Drug Conjugates (ADCs) Industry Drivers Table 15. Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges Table 16. Antibody Drug Conjugates (ADCs) Industry Restraints Table 17. Global Antibody Drug Conjugates (ADCs) Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Company (2021-2026) Table 19. Global Antibody Drug Conjugates (ADCs) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Antibody Drug Conjugates (ADCs) Key Company Head Office and Area Served Table 21. Global Antibody Drug Conjugates (ADCs) Company, Product Type & Application Table 22. Global Antibody Drug Conjugates (ADCs) Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Antibody Drug Conjugates (ADCs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Antibody Drug Conjugates (ADCs) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2021-2026) Table 29. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2027-2032) Table 30. Global Antibody Drug Conjugates (ADCs) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2021-2026) Table 34. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2027-2032) Table 35. AbGenomics Company Information Table 36. AbGenomics Business Overview Table 37. AbGenomics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio Table 39. AbGenomics Recent Development Table 40. ADC Therapeutics Company Information Table 41. ADC Therapeutics Business Overview Table 42. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio Table 44. ADC Therapeutics Recent Development Table 45. Astellas Pharma Company Information Table 46. Astellas Pharma Business Overview Table 47. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio Table 49. Astellas Pharma Recent Development Table 50. Genmab Company Information Table 51. Genmab Business Overview Table 52. Genmab Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Genmab Antibody Drug Conjugates (ADCs) Product Portfolio Table 54. Genmab Recent Development Table 55. Kairos Therapeutics Company Information Table 56. Kairos Therapeutics Business Overview Table 57. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio Table 59. Kairos Therapeutics Recent Development Table 60. Seattle Genetics Company Information Table 61. Seattle Genetics Business Overview Table 62. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio Table 64. Seattle Genetics Recent Development Table 65. Takeda Pharmaceuticals Company Information Table 66. Takeda Pharmaceuticals Business Overview Table 67. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio Table 69. Takeda Pharmaceuticals Recent Development Table 70. AbbVie Company Information Table 71. AbbVie Business Overview Table 72. AbbVie Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio Table 74. AbbVie Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bayer Antibody Drug Conjugates (ADCs) Product Portfolio Table 79. Bayer Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio Table 84. Pfizer Recent Development Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Roche Antibody Drug Conjugates (ADCs) Product Portfolio Table 89. Roche Recent Development Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Novartis Antibody Drug Conjugates (ADCs) Product Portfolio Table 94. Novartis Recent Development Table 95. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026) & (US$ Million) Table 96. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032) & (US$ Million) Table 97. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026) & (US$ Million) Table 98. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032) & (US$ Million) Table 99. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026) Table 101. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032) Table 102. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026) & (US$ Million) Table 103. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032) & (US$ Million) Table 104. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026) & (US$ Million) Table 105. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032) & (US$ Million) Table 106. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026) Table 108. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032) Table 109. China Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026) & (US$ Million) Table 110. China Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032) & (US$ Million) Table 111. China Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026) & (US$ Million) Table 112. China Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032) & (US$ Million) Table 113. Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026) & (US$ Million) Table 114. Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032) & (US$ Million) Table 115. Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026) & (US$ Million) Table 116. Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032) & (US$ Million) Table 117. Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026) Table 119. Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032) Table 120. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026) & (US$ Million) Table 121. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032) & (US$ Million) Table 122. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026) & (US$ Million) Table 123. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032) & (US$ Million) Table 124. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026) Table 126. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Antibody Drug Conjugates (ADCs) Product Image Figure 2. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Antibody Drug Conjugates (ADCs) Market Share by Type: 2025 VS 2032 Figure 4. Seattle Genetics Technology Image Figure 5. Immunomedics Technology Image Figure 6. ImmunoGen Technology Image Figure 7. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 14. Global Antibody Drug Conjugates (ADCs) Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Antibody Drug Conjugates (ADCs) Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Antibody Drug Conjugates (ADCs) Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Antibody Drug Conjugates (ADCs) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2021-2032) Figure 21. Global Antibody Drug Conjugates (ADCs) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2021-2032) Figure 23. North America Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 24. North America Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032) Figure 25. North America Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032) Figure 26. North America Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032) Figure 27. United States Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 28. Canada Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 30. Europe Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 31. Europe Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032) Figure 32. Europe Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032) Figure 33. Europe Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032) Figure 34. Germany Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 35. France Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 37. Italy Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 38. Russia Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 40. China Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 41. China Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032) Figure 42. China Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032) Figure 43. Asia Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 44. Asia Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032) Figure 45. Asia Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032) Figure 46. Asia Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032) Figure 47. Japan Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 51. India Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 52. Australia Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032) Figure 57. Brazil Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 62. UAE Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 64. Chile Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Seattle Genetics Technology
  • Immunomedics Technology
  • ImmunoGen Technology
Applications
  • Hospital
  • Clinics
  • Others
Companies covered
  • AbGenomics
  • ADC Therapeutics
  • Astellas Pharma
  • Genmab
  • Kairos Therapeutics
  • Seattle Genetics
  • Takeda Pharmaceuticals
  • AbbVie
  • Bayer
  • Pfizer
  • Roche
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Seattle Genetics Technology
  5. 1.2.3 Immunomedics Technology
  6. 1.2.4 ImmunoGen Technology
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinics
  11. 1.3.4 Others
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Antibody Drug Conjugates (ADCs) Growth Trends by Region
  14. 1.5.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Antibody Drug Conjugates (ADCs) Market Size by Region (2021-2026)
  16. 1.5.3 Antibody Drug Conjugates (ADCs) Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Antibody Drug Conjugates (ADCs) Market Dynamics
  1. 2.1 Antibody Drug Conjugates (ADCs) Industry Trends
  2. 2.2 Antibody Drug Conjugates (ADCs) Industry Drivers
  3. 2.3 Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges
  4. 2.4 Antibody Drug Conjugates (ADCs) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Antibody Drug Conjugates (ADCs) Revenue by Company (2021-2026)
  2. 3.2 Global Antibody Drug Conjugates (ADCs) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Antibody Drug Conjugates (ADCs) Key Company Head office and Area Served
  4. 3.4 Global Antibody Drug Conjugates (ADCs) Company, Product Type & Application
  5. 3.5 Global Antibody Drug Conjugates (ADCs) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Antibody Drug Conjugates (ADCs) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Antibody Drug Conjugates (ADCs) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Antibody Drug Conjugates (ADCs) Tier 1, Tier 2, and Tier 3
4 Antibody Drug Conjugates (ADCs) Market by Type
  1. 4.1 Global Antibody Drug Conjugates (ADCs) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2032)
  3. 4.3 Global Antibody Drug Conjugates (ADCs) Market Size Share by Type (2021-2032)
5 Antibody Drug Conjugates (ADCs) Market by Application
  1. 5.1 Global Antibody Drug Conjugates (ADCs) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2032)
  3. 5.3 Global Antibody Drug Conjugates (ADCs) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 AbGenomics
  2. 6.1.1 AbGenomics Company Information
  3. 6.1.2 AbGenomics Business Overview
  4. 6.1.3 AbGenomics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio
  6. 6.1.5 AbGenomics Recent Developments
  7. 6.2 ADC Therapeutics
  8. 6.2.1 ADC Therapeutics Company Information
  9. 6.2.2 ADC Therapeutics Business Overview
  10. 6.2.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
  12. 6.2.5 ADC Therapeutics Recent Developments
  13. 6.3 Astellas Pharma
  14. 6.3.1 Astellas Pharma Company Information
  15. 6.3.2 Astellas Pharma Business Overview
  16. 6.3.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio
  18. 6.3.5 Astellas Pharma Recent Developments
  19. 6.4 Genmab
  20. 6.4.1 Genmab Company Information
  21. 6.4.2 Genmab Business Overview
  22. 6.4.3 Genmab Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Genmab Antibody Drug Conjugates (ADCs) Product Portfolio
  24. 6.4.5 Genmab Recent Developments
  25. 6.5 Kairos Therapeutics
  26. 6.5.1 Kairos Therapeutics Company Information
  27. 6.5.2 Kairos Therapeutics Business Overview
  28. 6.5.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
  30. 6.5.5 Kairos Therapeutics Recent Developments
  31. 6.6 Seattle Genetics
  32. 6.6.1 Seattle Genetics Company Information
  33. 6.6.2 Seattle Genetics Business Overview
  34. 6.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio
  36. 6.6.5 Seattle Genetics Recent Developments
  37. 6.7 Takeda Pharmaceuticals
  38. 6.7.1 Takeda Pharmaceuticals Company Information
  39. 6.7.2 Takeda Pharmaceuticals Business Overview
  40. 6.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio
  42. 6.7.5 Takeda Pharmaceuticals Recent Developments
  43. 6.8 AbbVie
  44. 6.8.1 AbbVie Company Information
  45. 6.8.2 AbbVie Business Overview
  46. 6.8.3 AbbVie Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio
  48. 6.8.5 AbbVie Recent Developments
  49. 6.9 Bayer
  50. 6.9.1 Bayer Company Information
  51. 6.9.2 Bayer Business Overview
  52. 6.9.3 Bayer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Bayer Antibody Drug Conjugates (ADCs) Product Portfolio
  54. 6.9.5 Bayer Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Roche
  62. 6.11.1 Roche Company Information
  63. 6.11.2 Roche Business Overview
  64. 6.11.3 Roche Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Roche Antibody Drug Conjugates (ADCs) Product Portfolio
  66. 6.11.5 Roche Recent Developments
  67. 6.12 Novartis
  68. 6.12.1 Novartis Company Information
  69. 6.12.2 Novartis Business Overview
  70. 6.12.3 Novartis Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Novartis Antibody Drug Conjugates (ADCs) Product Portfolio
  72. 6.12.5 Novartis Recent Developments
7 North America
  1. 7.1 North America Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
  2. 7.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type
  3. 7.2.1 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026)
  4. 7.2.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032)
  5. 7.2.3 North America Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032)
  6. 7.3 North America Antibody Drug Conjugates (ADCs) Market Size by Application
  7. 7.3.1 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026)
  8. 7.3.2 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032)
  9. 7.3.3 North America Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032)
  10. 7.4 North America Antibody Drug Conjugates (ADCs) Market Size by Country
  11. 7.4.1 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
  13. 7.4.3 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
  14. 7.4.4 North America Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
  2. 8.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type
  3. 8.2.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032)
  6. 8.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Application
  7. 8.3.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032)
  10. 8.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Country
  11. 8.4.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
  2. 9.2 China Antibody Drug Conjugates (ADCs) Market Size by Type
  3. 9.2.1 China Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026)
  4. 9.2.2 China Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032)
  5. 9.2.3 China Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032)
  6. 9.3 China Antibody Drug Conjugates (ADCs) Market Size by Application
  7. 9.3.1 China Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026)
  8. 9.3.2 China Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032)
  9. 9.3.3 China Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
  2. 10.2 Asia Antibody Drug Conjugates (ADCs) Market Size by Type
  3. 10.2.1 Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032)
  6. 10.3 Asia Antibody Drug Conjugates (ADCs) Market Size by Application
  7. 10.3.1 Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032)
  10. 10.4 Asia Antibody Drug Conjugates (ADCs) Market Size by Country
  11. 10.4.1 Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst